BRAINPLUS UK LIMITED

What BRAINPLUS UK LIMITED does

BRAINPLUS UK LIMITED operates the Ayla digital dementia care platform under the parent company Brain+. Ayla is the first digital Cognitive Stimulation Therapy assistant certified as a medical device in the UK, delivering a NICE- and SCIE-aligned 14-session CST programme to care teams serving residents with mild to moderate dementia. The platform combines a clinical content library of 200+ evidence-based activities, on-screen guided session delivery that removes the need for clinical training, built-in outcome tracking with CQC-aligned reporting, multi-site management, and an integrated train-the-trainer certification module.

The company sells primarily on a per-care-home annual subscription at £2,500 per year, with unlimited platform access, onboarding, support, and training included. Go-to-market combines enterprise field sales to care home operators and NHS memory clinics with self-serve access for smaller homes, supported by NHS Clinical Entrepreneur Programme and Alzheimer's Society recognition that opens public procurement channels. Named customers include Southcare Homes Group, Agincare, and Age UK Tameside, with the company claiming 850+ organisations trust Ayla for dementia care therapy delivery.

Ayla generates documented clinical outcomes — including a 47.8% improvement in cognitive scores and a 66.3% boost in planning and decision-making in a 7-week Southcare Homes pilot — and posits an annual financial benefit of £113k-£200k per care home from improved occupancy, delayed care escalation, and reduced agency use. The company operates commercially in the UK and Denmark as a wholly-owned UK subsidiary of Brain+, with no disclosed funding rounds in the source material.

Name

BRAINPLUS UK LIMITED

Legal name

BRAINPLUS UK LIMITED

Website

https://ayla-care.com

Company type

Private

Founded year

2024

Operating status

Operating

Short description

BRAINPLUS UK LIMITED (trading as Ayla) provides the UK's first medical-device-certified digital Cognitive Stimulation Therapy platform for dementia care, selling per-care-home subscriptions to care home operators and NHS services in the UK and Denmark.

Ownership category

akta.pro rank

Product category

Dementia Care Software

NAICS

Continuing Care Retirement Communities and Assisted Living Facilities for the Elderly (6233), Services for the Elderly and Persons with Disabilities (624120)

SIC

Services-Prepackaged Software (7372), Services-Nursing & Personal Care Facilities (8050)

akta.pro primary industry

Cognitive Stimulation & Reminiscence Therapy (Non-Clinical) (HSABAEAH)

akta.pro secondary industry

Memory Care Care Management & Navigation (Dementia Care Coordination) (HLADACAJ)

Keywords

• Digital cognitive therapy
• Dementia care software
• Care home platform
• Medical device SaaS
• Cognitive stimulation therapy

Headquarters

HQ city

Warwick

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Annual Platform Subscription: Per care home annual subscription model at £2,500/year providing unlimited platform access, full onboarding, support, and training materials. No per-user fees or hidden charges. Revenue derived from recurring subscription fees from care home operators and NHS service providers.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

BRAINPLUS UK LIMITED, operating as Ayla Dementia Care, sells the Ayla platform—a digital Cognitive Stimulation Therapy (CST) assistant certified as a medical device in the UK. The software enables care home staff and NHS services to deliver a structured 14-session CST programme with over 200 evidence-based activities, guided on-screen prompts, and built-in outcome tracking. Customers subscribe on an annual per-site basis to use the platform for delivering non-drug dementia therapy.

Product overview

Ayla is a unified digital dementia care platform created by Brain+ UK LIMITED for delivering Cognitive Stimulation Therapy (CST) in care homes. The platform consists of the core Ayla CST assistant (the main product), which includes a 14-session structured CST programme, over 200 validated activities, guided session delivery with step-by-step prompts, built-in outcome tracking and reporting, and integrated staff training modules. The platform is designed for care teams without clinical backgrounds and supports both single-home and multi-site deployment. Pricing is £2,500/year per care home with unlimited access and full onboarding included.

Differentiator

Problem solved

Functional benefit

Products and services

• Ayla Digital CST Platform Ayla is a digital Cognitive Stimulation Therapy (CST) assistant and care platform that helps care teams deliver structured, evidence-based dementia therapy sessions. It is the first digital CST tool certified as a medical device in the UK, providing a 14-session programme, 200+ validated activities, guided on-screen delivery prompts, built-in outcome tracking, and integrated staff training. The product is sold on an annual subscription basis to care home operators and NHS service providers.

Quantifiable outcome

• 50% improvement in cognition in just 7 weeks
• +7 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• NHS Clinical Entrepreneur ProgrammecoreStrategic or Co-development Partner · 5 May 2025Ayla was selected for the Dementia Innovators Programme, a newly launched initiative by the NHS Clinical Entrepreneur Programme in partnership with the Alzheimer's Society. The programme supports high-potential innovations addressing critical needs in dementia care, offering participants direct access to NHS commissioners, clinicians and national networks. Brain+'s selection validates the clinical relevance of Ayla and is expected to advance commercial uptake through NHS-aligned pilot opportunities and public procurement engagement.
• Alzheimer's SocietycoreStrategic or Co-development Partner · 5 May 2025Co-partner with NHS Clinical Entrepreneur Programme in the Dementia Innovators Programme. Alzheimer's Society is the UK's leading dementia research charity providing strategic alignment and credibility for Ayla's clinical validation in the UK dementia pathway.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Altoida: Digital cognitive assessment platform using smartphone-based tasks and AI to detect early signs of cognitive impairment. Comparable as a regulated digital tool aimed at dementia detection and monitoring, addressing the same clinicians and life sciences partners as Ayla.
• Brain+ A/S (parent): Denmark-based parent of BRAINPLUS UK LIMITED, developing digital therapeutics for dementia and cognitive rehabilitation. Comparable as the originating developer of the Ayla CST programme and the likely R&D and capital backbone for the UK entity.
• Neurotrack Technologies: Digital cognitive assessment and brain health platform with a focus on early dementia risk identification. Comparable as a digital dementia-focused health platform building outcome-driven tools, although it focuses more on assessment and risk than on therapy delivery.

Direct peers

• KareInn: UK care home digital care planning and evidence platform. Direct peer because it sells subscription software to UK care homes for daily care documentation, CQC evidence, and outcomes reporting, overlapping Ayla's evidence and CQC reporting value proposition.
• Birdie: UK home care SaaS platform for care agencies and care homes, covering care planning, eMAR, and outcomes. Comparable to Ayla as a B2B subscription platform sold into UK care providers, focused on digitising and evidencing daily care delivery.
• Care Vision: UK care home management software covering care planning, eMAR, and resident engagement. Comparable as a UK care home SaaS subscription that competes for the same digital transformation budget and CQC evidence use case as Ayla.
• CogniFit: Digital cognitive assessment and brain training platform used by clinicians, researchers, and consumers. Comparable because it sells structured, evidence-based cognitive exercises — the same underlying activity content Ayla curates for CST — into both clinical and consumer channels.
• Person Centred Software: UK-based care home software platform providing electronic care planning, observations, and reporting. Highly comparable because it targets the same UK care home buyer with a SaaS subscription, embeds into CQC workflows, and competes for the same digital-health line item in care home budgets.
• Constant Therapy Health: Digital cognitive, speech, and language therapy platform with clinician and consumer tiers. Comparable to Ayla as a regulated, evidence-based digital therapy product sold on subscription to providers serving neurological and cognitive conditions.

Regional players

• Whzan Digital Health: UK-based digital health platform providing remote monitoring and telehealth tools into care homes and community services via NHS pathways. Comparable because it sells digital tools into UK care homes through NHS commissioning channels, addressing a similar buyer to Ayla.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ayladementia

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BRAINPLUS UK LIMITED